In a report released on February 7, Pablo de Renteria from Kepler Capital maintained a Buy rating on Laboratorios Farmaceuticos Rovi (0ILL – Research Report), with a price target of €102.50.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback